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Definition and Diagnosis 
Anxiety and depressive disorders are common neuropsychiatric complications of Parkinson’s disease 
(PD). Whilst they may have particular characteristics (1), and their assessment is complicated by the 
overlap of symptoms with other manifestations of PD, there is no clearly defined difference to 
depressive or anxiety disorders in non-PD patients. Therefore, diagnosis of anxiety and depressive 
disorders is based on standard criteria, including ICD-10 diagnostic criteria and the definitions of 
anxiety and depressive disorders in the DSM Diagnostic and Statistical Manual of Mental Disorders 
(DSM) 5 criteria by the American Psychiatric Association (see box 1):  
Box 1: Major Depressive Disorder 
A. Five (or more) of the following symptoms have been present during the same 2-week 
period and represent a change from previous functioning; at least one of the symptoms is 
either (1) depressed mood or (2) loss of interest or pleasure. 
1. Depressed mood most of the day, nearly every day, as indicated by either 
subjective report (e.g., feels sad, empty, hopeless) or observation made by others 
(e.g., appears tearful). (Note: In children and adolescents, can be irritable mood.) 
2. Markedly diminished interest or pleasure in all, or almost all, activities most of the 
day, nearly every day (as indicated by either subjective account or observation.) 
3. Significant weight loss when not dieting or weight gain (e.g., a change of more 
than 5% of body weight in a month), or decrease or increase in appetite nearly every 
day. (Note: In children, consider failure to make expected weight gain.) 
4. Insomnia or hypersomnia nearly every day. 
5. Psychomotor agitation or retardation nearly every day (observable by others, not 
merely subjective feelings of restlessness or being slowed down). 
6. Fatigue or loss of energy nearly every day. 
7. Feelings of worthlessness or excessive or inappropriate guilt (which may be 
delusional) nearly every day (not merely self-reproach or guilt about being sick). 
8. Diminished ability to think or concentrate, or indecisiveness, nearly every day 
(either by subjective account or as observed by others). 
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation 
without a specific plan, or a suicide attempt or a specific plan for committing suicide. 
B. The symptoms cause clinically significant distress or impairment in social, occupational, or 
other important areas of functioning. 
C. The episode is not attributable to the physiological effects of a substance or to another 
medical condition. 
Note: Criteria A-C represent a major depressive episode. 
D. The occurrence of the major depressive episode is not better explained by schizoaffective 
disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified 
and unspecified schizophrenia spectrum and other psychotic disorders. 
E. There has never been a manic episode or a hypomanic episode. 
Note: This exclusion does not apply if all of the manic-like or hypomanic-like episodes are 
substance induced or are attributable to the physiological effects of another medical 
condition. 
Adapted from: Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 criteria, The 
American Psychiatric Association, 2013. 
Box 2: Generalised Anxiety Disorder 
A. Excessive anxiety and worry (apprehensive expectation), occurring more days than not for 
at least 6 months, about a number of events or activities (such as work or school 
performance). 
B. The individual finds it difficult to control the worry. 
C. The anxiety and worry are associated with three (or more) of the following six symptoms 
(with at least some symptoms having been present for more days than not for the past 6 
months): 
Note: Only one item required in children. 
1. Restlessness, feeling keyed up or on edge. 
2. Being easily fatigued. 
3. Difficulty concentrating or mind going blank. 
4. Irritability. 
5. Muscle tension. 
6. Sleep disturbance (difficulty falling or staying asleep, or restless, unsatisfying 
sleep). 
D. The anxiety, worry, or physical symptoms cause clinically significant distress or 
impairment in social, occupational, or other important areas of functioning. 
E. The disturbance is not attributable to the physiological effects of a substance (e.g., a drug 
of abuse, a medication) or another medical condition (e.g., hyperthyroidism). 
F. The disturbance is not better explained by another medical disorder (e.g., anxiety or worry 
about having panic attacks in panic disorder, negative evaluation in social anxiety disorder 
[social phobia], contamination or other obsessions in obsessive-compulsive disorder, 
separation from attachment figures in separation anxiety disorder, reminders of traumatic 
events in posttraumatic stress disorder, gaining weight in anorexia nervosa, physical 
complaints in somatic symptom disorder, perceived appearance flaws in body dysmorphic 
disorder, having a serious illness in illness anxiety disorder, or the content of delusional 
beliefs in schizophrenia or delusional disorder). 
Adapted from: Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 criteria, The 
American Psychiatric Association, 2013. 
 
The types of depressive disorders seen in PD include major depression, minor depression and 
dysthymia. Patients with minor depressive disorder patients do not formally DSM V satisfy criteria 
but suffer from significant depressive symptoms interfering in their lives (2). Dysthymia, now called 
persistent depressive disorder in DSM V, is major depressive disorder lasting for at least 2 years (3). 
However, subsyndromal depression not fulfilling full diagnostic criteria for depression is common 
and should be included in the assessment of depressive symptoms of PD (4). Anxiety can present  
with panic attacks, phobias or generalized anxiety disorder (5). Both disorders in PD can be episodic 
or non-episodic, and may be associated with off-periods, with or without motor features (6).  
 
Subtypes of depression and anxiety in PD 
Within the definitions of anxiety and depressive disorders, the symptoms of depression and anxiety 
in patients with PD vary. The PROMS-PD study sub-classified PD patients according to their 
neuropsychiatric phenotype (7, 8) into four clinical phenotypes: anxious-depressed, predominantly 
depressed, predominantly anxious and healthy subgroup. The investigators reported that the 
depression phenotype was related to more axial motor symptoms, whereas anxiety was more 
commonly found among patients with motor fluctuations as well as younger age of onset (below the 
age of 55 years). Patients with the postural instability and gait disorder (PIGD) or non-tremor 
dominant motor subtypes were more likely to be represented in any of the mood subgroups when 
compared with non-PIGD and tremor-dominant patients. Furthermore, cognition was found to be a 
predictor of depression but not anxiety scores. 
 
Epidemiology 
Assessment of prevalence of depression and anxiety in PD is often complicated by overlap of somatic 
features of depression with other features of PD, coexisting cognitive problems and side-effects of 
dopaminergic medication (9). However, depressive symptoms in PD are reported to be present in 
approximately 20-30% of patients with PD (10), with wide variation between studies, ranging from 
2.7% to up to 90% in the literature (11). In a review by Reijenders et al (11), the weighted prevalence 
of major depressive disorder was 17%, that of minor depressive symptoms 22% and dysthymia 13%. 
The authors concluded an increased prevalence of depression in PD, but lower than generally 
assumed. Whilst depressive symptoms are also common in the general population, they have clearly 
been shown to be more frequent in PD patients than age-matched populations, and they are also 
more common in this neurological condition than in other health problems such as diabetes or 
osteoarthritis (12).  In table 1, a summary of the reported prevalence rates of the different degrees 
of depressive symptomatology are shown.  
Although anxiety is often assessed together with depression and is often comorbid with depression 
(13) (14), it can occurr independently and has been reported to exert a higher impact on quality of 
life among PD patients than depression itself (15, 16). Studies on the prevalence of anxiety are 
scarce and complicated by symptom overlap and comorbid disorders. Report prevalence rates range 
from 25% to 52% (17-20). Table 2 summarizes the prevalence of anxiety in PD among different 
studies.  
Overall, depression and anxiety are both inadequately recognized as complications of PD in daily 
clinical practice, and are not diagnosed in up to 50% of PD patients, although they are more 
frequently recognised than some other non-motor features, such as those possibly considered more 
embarrassing (21-23).  
In the prediagnostic phase of PD, depression and initiation of an antidepressant treatment are 
associated with an increase of PD risk of PD with an OR of 1.8 to 2.4 (24-27). Studies have also shown 
a link between existence of anxiety and the development of PD with a relative risk of 1.5 to 1.6 (24, 
28, 29). A premorbid Parkinsonian personality with anxious traits has also been suggested, with 
lower novelty seeking behaviour and higher harm avoidance (13, 30) (31).  
Risk factors for the development of depression in PD patients have been examined in large scale 
studies, reporting an increased risk among women, in the advanced stages of PD and in patients with 
cognitive impairment (32).   
Genetic risk factors for the development of depression or anxiety in PD have so far shown 
inconsistent results (33-36), although one study has suggested that depression is more common 
among carriers of the Gly2019Ser mutation in the LRRK2 gen, when compared with non-carriers 
(37). A longitudinally followed GBA mutation positive cohort was found to have higher scores of 
depression (38). The relationship between PARK2, PINK1, PARK7 and DJ1mutations and 
depression/anxiety has also been studied, but no clear correlation could be found between the 
mutation carriers and the non-carriers for these genes has been found (39-45).  
Risk factors associated with anxiety were examined in a longitudinal study by Zhu et al, who 
reported that depressive symptoms, insomnia, dysautonomia and cognitive impairment were risk 
factors associated with higher HADS-A scores (29).  
 
Impact on Quality of life 
Anxiety and depression have also been shown to be determinants of poorer quality of life in PD 
patients (23, 46-55). They result in a reduced health-related quality of life, worse functional status 
and worse cognitive function (56), and have been linked with an increased mortality (57). Whilst 
greater evidence exists for the impact of depressive disorders on quality of life, some studies found 
anxiety to be the main related neuropsychiatric disorder contributing to impaired quality of life (55, 
58, 59) (60). One study reported two distinct patterns, distinguishing the impact of depression 
mainly on the ‘mental component’ from the impact on anxiety mainly based on the ‘physical 
component’ of quality of life measured by the SF-36 scale (61). In table 3, the effect of 
neuropsychiatric comorbidity on quality of life among PD patients in different studies is shown. 
 
Scales for depression and anxiety 
As depression and anxiety cause considerable burden on patients’ and carers’ quality of life and 
effective treatment has the potential to improve these symptoms and thereby outcome and 
prognosis of PD patients, early detection and diagnosis are important. Although common and 
relevant to quality of life, they remain undetected in up to 50% of PD patients (9, 22, 62), and 
screening tools such as scales and questionnaires have an important role in clinical practice and 
research.  
Depression 
Several reviews for screening and rating scales for depression have been published. An evaluation of 
screening methods for depression by the American Academy of Neurology (AAN)  in 2006 concluded 
that the Beck Depression Inventory (BDI), Hamilton Depression Rating Scale (HAMD 17) and 
Montgomery Asberg Depression Rating (MADRS)  Scale had the highest diagnostic accuracy and 
were adequate to screen PD patients (evidence level B) and highlighted the need for specific 
validation (63). Similarly, in 2007 a review by the MDS Task Force on Depression rating scales was 
published, concluding that the Ham-D, BDI, HADS, MADRS and GDS are appropriate as screening 
scales for depression in PD with the CES-D and CSDD as alternative requiring further validation (64). 
Williams et al (65) compared 9 scales for the assessment of depression in PD of which the GDS-30 
was judged the most efficient screening tool for depression in PD. A more recent review by Torbey 
et al (66) concluded that the HAM-D and the self-report GDS scales are recommended for screening 
and measuring severity of depression in PD, with the HADS-D, HDI, and the BDI, and MADRS being 
valid in PD and the CSDD for screening for PD in patients with and without dementia. Table 4 shows 
the cut-off scores for the different validated scales for depression in PD (62). 
Anxiety 
The use of validated scales for assessment of anxiety in PD was also reviewed by a MDS Task Force in 
2008 (67), assessing the following scales: Beck Anxiety Inventory (BAI), Hospital Anxiety And 
Depression Scale-Anxiety (HADS-A), Zung’s Self-Rating Anxiety Scale (Zung’s SAS), Anxiety Sensitivity 
Index (ASI), State-Trait Anxiety Inventory (STAI), Hamilton Anxiety Rating Scale (HARS) and section 5 
of Neuropsychiatric Inventory (NPI). Since there were no scales fulfilling criteria for a recommended 
scale for the assessment of anxiety in PD at that point of time, further validation studies were 
recommended. Since then, the three most commonly applied scales, BAI, HADS and HARS, have 
been validated for use in PD. Due to limitations of all existing scales for assessment of anxiety in PD, 
the Parkinson Anxiety Scale (PAS), a PD specific anxiety scale, was developed and reported to have 
higher specificity and sensitivity for its use as a screening tool than other scales (68). Another anxiety 
scale for PD patients, the Geriatric Anxiety Inventory (GAI), was developed and validated (69), but 
further large scale studies to validate these scales in other populations are required.  
 
Biomarkers in depression and anxiety in PD 
It has been suggested that in depression there is dysfunction of both dopamine and serotonin 
systems and their interaction in the brain, contributing to the development of depressive disorders. 
To date, only a few studies have assessed this interconnection, with important results coming from 
PET imaging models (70). In rat models, Lee et al found a correlation between a decrement of 5HT-
1A receptor binding sites and depression severity. In studies on depression in humans, Drevets et al 
(71) found reduced 5-HT1A receptor binding sites and reduced serotonin mRNA expression in post-
mortem analysis of the brainstem of suicide victims. A recent review on PET imaging and depression 
by Savitz et al (72) however highlighted mixed results in the literature, some groups reporting a 
decrease in 5HT-1A receptor binding sites and others hypothesizing an elevation in pre- and 
postsynaptic binding sites (73). They further hypothesized reduced 5-HT 2A, 5-HT 1B, Dopamine D1, 
MAO-A and muscarinic M2 receptor binding in patients with mood disorders and concluded that the 
role of D2/D3 receptor binding sites is currently unclear, suggesting the current need for further 
studies.  
In PD, there is evidence from imaging studies for both serotonergic (74) and dopaminergic 
dysfunction. Structural imaging suggests increased frontal atrophy in depressed patients with PD as 
the most strongly associated neural correlate of neuropsychiatric symptomatology in PD (75). In 
addition, hyperperfusion in occipital areas and hypoperfusion in fronto-temporo-limbic areas was 
reported as a potential biomarker for depression in PD (76), and a significant increase in amygdala 
metabolism in depressed PD patients and decreased caudate metabolism in anxious PD patients 
(77). In another neuroimaging study of depression, anxiety and apathy in PD increased neural 
activity in prefrontal regions and decreased functional connectivity between prefrontal and limbic 
structures was found in depressed PD patients with an inverse correlation between dopaminergic 
density in the caudate and putamen and the severity of anxiety in PD patients (78). However, further 
studies to assess potentially involved pathways of neuropsychiatric symptoms in PD are needed. 
Blood based biomarkers are of increasing interest in PD with one study reporting that lower plasma 
levels of peripheral levels of 5-HT and its metabolite 5-HIAA in PD patients correlate with more 
severe depression and with pain (79). The same group also studied correlations between plasma 
levels of amino acids and non-motor symptoms and found a correlation between lower levels of ASP 
and Glutamate and depression as well as sleep disturbances (80). Some other recent studies found a 
relation between anxiety/depression and lower uric acid levels in serum (81, 82). Studies on 
inflammatory markers in the cerebrospinal fluid of PD patients, have indicated higher levels of 
inflammatory parameters such as Interleukin-1 beta, Interleukin-6 and Tumor necrosis factor Alpha 
in PD patients (83, 84) and have more recently also been linked with non-motor symptoms in PD 
(85). A recent study on inflammatory biomarkers in depression in PD by Lindqvist et al (86) 
specifically correlated HADS depression score with higher CRP levels and HADS anxiety score with IP-
10 positivity.  
 
Management 
Depression 
Pharmacological treatment 
Although the prevalence of depression and anxiety among PD patients is high and both 
neuropsychiatric features have a significant impact on quality of life, evidence to guide their 
treatment is insufficient. Efficacy has been reported for the tricyclic antidepressants (TCA) 
Desipramine and Nortriptyline, the Serotonin-Noradrenaline reuptake inhibitors (SNRI) Venlafaxine, 
and the selective Serotonin reuptake inhibitors (SSRI) Citalopram, Sertraline and Paroxetine and in 
randomized, double-blind, placebo-controlled clinical trials (87-89). However, sample sizes of these 
studies were small and there is currently still inconclusive evidence on the effectiveness of individual 
antidepressants compared to each other and even against placebo. Nonetheless, in a recent 
systematic review on systematic treatments for depression in PD comparing 13 interventional trials, 
only SSRIs showed a statistically significant improvement of depression (90, 91). In contrast, other 
studies concluded tricyclic antidepressants to be at a similar level of efficacy as SSRIs (92-94). There 
is also evidence that dopamine agonists improve depression when compared with placebo, with 
most evidence available for Pramipexole (95) and transdermal Rotigotine (96). An MDS Evidence-
based Review concludes that Pramipexole is efficacious for the treatment of depression in PD (97). 
The importance of dopaminergic agents in the occurrence of mood disorders of PD is also reflected 
in the development of depression in the context of dopamine withdrawal syndrome (DAWS) and 
increased rates of apathy and depression following rapid medication reduction after Deep Brain 
Stimulation surgery (98). 
The results of pharmacological trials for depression in PD is summarised in table 2. 
Current guideline by the AAN state that the TCA Amitriptyline (level C) may be considered for 
treatment of depression in PD, with currently insufficient evidence to make recommendations on 
other pharmacological treatments. A more recent meta-analysis with slightly different methodology 
by Liu et al comparing the efficacy and acceptability of different medications for depression in PD, 
concluded that TCAs might be the best choice when starting antidepressant treatment in PD due to 
its favourable balance between benefit and acceptability, followed by Pramipexole, SNRIs and SSRIs 
(99). Other meta-analyses however concluded that whilst both SSRI and TCA are effective, SSRIs 
have been tolerability in PD (100) or that the antidepressant effect is only significant for SSRIs and 
not TCA. 
 
 
Non-pharmacological treatment 
A multidisciplinary approach improves depression scores in PD (101), and can include education 
about the mood disturbances and its relation to PD, use of skills to cope with these symptoms and 
emotional support (102), as well as more specific pharmacological and non-pharmacological  
approaches. Increasingly evidence is emerging on the role of more specific non-pharmacological 
options. The best evidence exists for cognitive behavioural therapy (CBT), and with evidence for 
other non-pharmacological interventional strategies (103), including transcranial magnetic 
stimulation and deep brain stimulation that need further evaluation. 
In addition to several smaller publications (103-105), a large controlled trial of cognitive behavioural 
therapy (CBT) for depression and anxiety in PD patients (106) showed significant improvement of 
HAM-D scores when comparing 10 sessions of CBT plus clinical monitoring with clinical monitoring 
only in a cohort of 80 patients, including longer-term effects. A systematic review of CBT therapy for 
depression in PD by Egan et al, found two randomized controlled trials where significant reductions 
in depression scores could be seen, with a maintenance of the effect over the follow-up periods of 1- 
and 6-months. Although the authors concluded that CBT shows promising evidence of efficacy in the 
treatment of depression and anxiety in PD, they recommend further large-scale studies with longer 
follow-up periods (107).  
Transcranial magnetic stimulation (TMS) for the treatment of mood symptoms in PD has also been 
assessed in a number of small studies with some encouraging results in some. Whilst there was no 
clear evidence of an improvement of mood symptoms when compared to sham-TMS (108, 109), 
others concluded some beneficial effect of TMS on depression (110). Further large-scale studies are 
needed. 
Deep brain stimulation (DBS) has been associated with worsening mood as well as apathy scores 
(111). However, a review of the effect of DBS on depression in (112) concluded that the results on 
depression were inconsistent, likely due to the variation in anatomical targets (113-115). However, 
there a comparison of differential outcomes depending on target selection did not identify any 
significant differences (116). However, the risk of suicide following DBS surgery has been reported to 
be significantly increased and needs particular attention (117). 
Anxiety 
Anxiety has been given less attention than depression, although its prevalence is similar to that of 
depression in PD and overlap between both is commonly observed. Treatment of anxiety in PD has 
not been assessed systematically and in large-scale studies. There are currently no randomized, 
controlled trials for treatment guidelines on anxiety in PD. The MDS Evidence-based medicine review 
on the treatment of anxiety in PD insufficient evidence as to make recommendations (97).  
Conclusions 
Understanding of the features, pathophysiology and management of depression and anxiety in PD is 
increasing, but appropriate management of these neuropsychiatric features still poses an important 
unmet need in PD patients. Their high prevalence and impact on quality of life highlight the 
importance of an early detection and detection of biomarkers and risk factors, and better evidence 
on treatment approaches. Early detection, thorough assessment and adequate treatment can 
provide substantial improvement in the overall management of patients with PD. Validation of 
clinical scales, especially for anxiety, and development of biomarkers, and large scale trials to guide 
management of depression with pharmacological and non-pharmacological options are urgently 
needed.  
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Tables 
 
Table 1: Prevalences (%) of depression in PD among various studies. Taken from A systematic review 
of prevalence studies of depression in Parkinson's disease. Reijnders JS et al. Movement disorders: 
Official journal of the Movement Disorder Society, 2008.  
 
Reference (11) 
 
 
 
 
 
 
 
 
 
 
 
Study Sample Sample size Quality score Major depressive disorder Minor depression Dysthymia Clinically relevant depressive symptoms
Structured clinical interview
Starkstein et al. (1990) Outpatient clinic 105 5 21 20 41
Starkstein et al. (1992) Outpatient clinic 92 5 20 21 41
Hantz et al. (1994) Population 73 7 2.7 2.7
Starkstein et al. (1996) Outpatient clinic/dementia 33 6 30 27 57
Liu et al. (1997) Outpatient clinic 109 5 16.5 25.7 42.2
De Rijk and Bijl (1998) Population 384 5 2.3 4.7 7
Starkstein et al. (1998) Outpatient clinic 112 6 22 31.3 53.3
Leentjens et al. (2000) Outpatient clinic 63 6 25 25
Leentjens et al. (2000) Outpatient clinic 53 6 23 23
Anguenot et al. (2002) Outpatient clinic 135 6 55.6 2.2 57.8
Naarding et al. (2002) Outpatient clinic 85 6 23.5 23.5
Weintraub et al. (2003) Outpatient clinic 77 6 20.8 13 33.8
Lauterbach et al. (2004) Outpatient clinic 28 5 14.3 3.6 17.9
Nuti et al. (2004) Outpatient clinic 90 6 21.1 18.8 39.9
Ertan et al. (2005) Outpatient clinic 109 6 22.9 28.4 51.4
Papapetropoulos et al. (2005) Brain bank data 67 7 43.3
Costa et al. (2006) Inpatient clinic 58 5 20.7 34.5 55.2
Costa et al. (2006) Inpatient clinic 83 6 21.7 25.3 47
Visser et al. (2006) Outpatient clinic 92 6 19 19
Wichowicz et al. (2006) Population 100 6 35 35
Clinical interview
Santamaria et al. (1986) Outpatient clinic/recent onset 34 4 2.9 29.4 32.3
Mayeux et al. (1988) Outpatient and inpatient clinic 339 4 47
Brown and MacCarthy (1990) Outpatient clinic 40 6 25
Aarsland et al. (1996) Population 235 6 7.7 7.7
Tandberg et al. (1996) Population 245 6 7.7 7.7
Tandberg et al. (1997) Population 245 6 7.7 7.7
Tandberg et al. (1998) Population 239 6 7.8 7.8
Aarsland et al. (1999) Population 235 5 7.2 7.2
Karlsen et al. (1999) Population 233 6 7.7 7.7
Cubo et al. (2000) Outpatient clinic 88 5 7.3 7.3
Giladi et al. (2000) Outpatient clinic 172 5 33
Larsen et al. (2000) Population 240 6 7.6 7.6
Krishnan et al. (2003) Outpatient clinic 126 5 12.7
Rating scale
Mindham (1970) Inpatient psychiatric hospital 89 3 89
Tison et al. (1995) Outpatient clinic and nursing home 60 6 32.7
Meara et al. (1999) General Practice 132 5 64
Schrag et al. (2000) General Practice 92 5 19.6
Happe et al. (2001) Outpatient clinic 56 4 76.4
Schrag et al. (2001) General Practice 97 5 19.6
Shulman et al. (2001) Outpatient clinic 99 3 36
Happe et al. (2002) Outpatient clinic 116 4 37.1
Marinus et al. (2002) Outpatient clinic 177 4 38.4
Schrag et al. (2002) General Practice 128 5 20
Shulman et al. (2002) Outpatient clinic 101 3 44
Rojo et al. (2003) Outpatient clinic 353 4 56.9
Hely et al. (2005) Outpatient clinic 52 4 53.6
Holroyd et al. (2005) Outpatient clinic 100 4 15
Kang et al. (2005) Population 193 5 13
Prado and Barbosa (2005) Outpatient clinic 60 4 38.3
Kirsch-Darrow et al. (2006) Outpatient clinic 80 3 26.3
Weintraub et al. (2006) Outpatient clinic 130 4 36.2
Weighted mean 5.1 17 22 13 35
  
Table 2: Overview of studies reporting clinically relevant anxiety symptoms in PD according to 
validated rating scales. Taken from Prevalence of anxiety in Parkinson's disease: A systematic review 
and meta-analysis. Broen MP et al. Movement disorders: official journal of the Movement Disorder 
Society, 2016. 
 
 
a: Drug naïve. 
Reference (20) 
Study Sample Sample size Quality score Scale used Cut-off score used
Clinically relevant anxiety 
symptoms, %
Marinu et al (2002)
Outpatient 
clinic
177 16 HADS ≥11 19.8
Carod-Artal et al (2007)
Outpatient 
clinic
144 14 HADS ≥11 23.6
Mondolo et al (2007)
Outpatient 
clinic
46 14 HADS ≥8 10.8
Carod-Artal et al (2008)
Outpatient 
clinic
115 14 HADS ≥11 30.4
McKinley et al (2008)
Outpatient 
clinic
42 15 HADS ≥8 16
Havlikova et al (2008)
Outpatient 
clinic
150 14 HADS ≥11 30.6
Kulisevsky et al (2008)
Outpatient 
clinic
1351 19 HADS ≥11 20.8
Rodriquez-Blastez et al (2009)
Outpatient 
clinic
387 14 HADS ≥11 22
Negres-Pages et al (2010) Population 422 17 HADS ≥11 (≥8) 27 (51)
Hu et al (2011) Population 197 14 HADS ≥11 32
Brown et al (2011)
Outpatient 
clinic
513 16 HADS ≥11 22
Ozdilek et al. (2012)
Outpatient 
clinic
50 14 HADS ≥10 18
Quelhas et al (2014)
Outpatient 
clinic
33 14 HADS ≥11 (≥8) 18.2 (54.5)
Fereshtehnejad et al (2015)
Outpatient 
clinic
140 14 HADS ≥8 38.9
Borek et al. (2006)
Outpatient 
clinic
120 16 HARS ≥14 23.2
Stefanova et al (2013)
Outpatient 
clinic
360 19 HARS ≥11 37.8
Jiang et al (2015)
Outpatient 
clinic
99 14 HARS >11 25.3
Wu et al (2015)
Outpatient 
clinic
301 15 HARS >14 10.6
Schulman et al (2001)
Outpatient 
clinic
101 16 BAI ≥10 39
Rutten et al (2015)
Outpatient 
clinic
294 16 BAI >12 45
Yamanashi et al (2013)
Outpatient 
clinic
117 15 STAI
41 (men) 42 
(women)
55
Weintraub et al (2015)[1]
Outpatient 
clinic
423 15 STAI >39 24.6
Siri et al (2010) Population 486 15 SCL-90 >1 46
Bugalho et al (2012)
Outpatient 
clinic
36 15 SCL-90-R >1 28
Henderson et al (1992)
Outpatient 
clinic
164 16 Zung >49 15
Baig et al (2015)
Outpatient 
clinic
769 17
Leeds anxiety 
score
>7 17.3
Aarsland et al (2009) a Population 175 16 NPI ≥4 6.9
Glossary: BAI, Beck Anxiety Inventory; HADS, Hospital Anxiety and Depression Scale; HARS, Hamilton 
Anxiety Rating Scale; NPI, Neuropsychiatric Inventory; SCL-90, Symptom Checklist-90; STAI, State-
Trait Anxiety Inventory. 
 
Table 3: Determinants of health-related quality of life in PD. Taken from Neuropsychiatric symptoms, 
behavioural disorders, and quality of life in Parkinson's disease. Balestrino R et al, Journal of the 
neurological sciences, 2017.  
 
Reference: (46)  
 
Glossary: ICDs, impulse control disorders; DDS, dopamine dysregulation syndrome; NPS, 
neuropsychiatric symptoms. 
 
 
 
 
References N. Specific for NPS NPS considered in the regression analysis NPS determinants of HRQoL
1. Cross-sectional studies
Greene et al. 51 Yes Depression Depression
Carod-Artal et al. 115 No Depression, anxiety Depression, anxiety
Klepac et al. 124 Yes Depression Depression
McKinlay et al. 49 No Depression, apathy, anxiety, hallucinations Anxiety, depression, hallucinations
Muslimovic 190 No Depression, anxiety Depression, anxiety
Rahman 130 No Depression, anxiety Depression, anxiety
Qin 391 No Depression Depression
Quelhas et al. 46 No Depression, anxiety Anxiety
Žiropađa et al. 102 No Depression Depression
Gallagher 89 No Apathy, psychosis, depression, anxiety, mood/apathy, Depression
perception problem/hallucinations
Naismith et al. 35 No Depression Depression
Winter et al. 81 No Depression Depression
Benito-León et al. 557 Yes Apathy Apathy
Gómez-Esteban et al. 99 Yes NPS NPS
Martinez-Martin 411 No Mood/apathy, perception problem/hallucinations Mood/apathy
Leroi et al. 99 No Depression, anxiety, impulsiveness Depression, impulsiveness
Winter et al. 70 No Depression Depression
Bach et al. 1449 No Depression, psychosis/hallucinations Depression, psychosis
Hanna et al. 38 Yes Anxiety, depression Anxiety, depression
Dubayova et al. 153 No Depression, anxiety Depression, anxiety
Rodrìguez-Violante et al. 177 No Mood/apathy, perception problem/hallucinations Mood/apathy
Santos-García et al. 150 No Depression Depression
Duncan 158 No Mood/apathy, perception problem/hallucinations, Depression, anxiety
depression
Lawson et al. 219 Yes Depression, NPS Depression, NPS
Phu 100 Yes ICDs and related behaviours, depression Depression, ICDs and related behaviours
Alvarado Bolaños et al. 492 Yes Psychotic symptoms, mood/apathy, ICDs Mood/apathy, ICDs
Fereshtehnejad et al. 157 No Depression, anxiety, psychosis, apathy Anxiety, depression
Jones et al. 107 Yes Depression, anxiety, apathy Anxiety
Kadastik-Eerme et al. 268 No Depression Depression
Skorvanek et al. 291 No Depression, anxiety, psychosis, DDS DDS
Diaz et al. 59 No Depression, anxiety Anxiety, depression
Fan et al. 134 No Depression, anxiety Depression, anxiety
Rieu 136 Yes Depressive mood, hypomanic mood, anxiety, Hyperemotionality
irritability and aggressiveness, hyperemotionality, 
psychotic symptoms, nocturnal hyperactivity, eating behavior, 
creativity, hobbyism, punding, risk-taking behavior, 
compulsive shopping, pathological gambling, hypersexuality,
dopaminergic addiction, excess in motivation
Vela et al. 87 Yes Depression, ICDs Depression
2. Longitudinal studies
Forsaa et al. 82 No Depression, psychosis Depression
Marras et al. 362 No Depression Depression
Müller 166 No Depression, apathy Depression
Prakash et al. 227 No Apathy, attention, memory, hallucinations, delusions, Mood/apathy
depression, anxiety, anhedonia
Table 4: Recommended cut-off scores and performance of screening instruments for depression in 
PD. Taken from Accuracy of screening instruments for detection of neuropsychiatric syndromes in 
Parkinson's disease. Martinez-Martin P et al. Movement disorders : official journal of the Movement 
Disorder Society, 2016. 
 
Reference (62) 
Glossary: PPV, Predictive Positive Value; PNV, Predictive Negative Value; BDI, Beck 
Depression Inventory; CESD-R, Center for Epidemiologic Studies Depression Rating Scale–Revised; 
CSDD, Cornell Scale for Depression in Dementia; GDS, Geriatric Depression Scale; HADS, Hospital 
Anxiety and Depression Scale; HADS-D, Depression subscale; HAMD-17, Hamilton Depression Rating 
Scale; IDS-C, Inventory of Depressive Symptoms–Clinician; IDS-SR, Inventory of Depressive 
Symptoms–Patient; MADRS, Montgomery-Asberg Depression Rating Scale; NICE, UK National 
Institute for Health and Clinical Excellence; PHQ, Patient Health Questionnaire; UPDRS-D, Unified 
Parkinson's Disease Rating Scale–Depression; WHO-5, WHO-Five Well-being Index; Zung's SDS, 
Zung's Self-rating Depression Scale. 
 
 
 
 
 
 
 
Cut-off score Sensitivity (%) Specificity (%) PPV (%) NPV (%) Reference
BDI-I 8/9 92 59 39 96 Leentjens AF et al, 2000
BDI-II 6/7 95 60 62 94 Williams JR et al, 2012
CESD-R 11/12 72 70 62 79 Williams JR et al, 2012
CSDD 5/6 83 73 54 92 Williams JR et al, 2009
GDS-15 4/5 88 85 61 96 Weintraub D et al, 2006
5/6 84 89 59 97 Baillon S et al, 2014
7/8 78 88 67 93 Chagas MH et al, 2010
6/7 79 88 66 93 Chagas MH et al, 2013
GDS-20 10/11 100 76 33 100 Mondolo F et al, 2006
GDS-30 9/10 81 84 58 94 McDonald Wmet al, 2006
9/10 89 62 71 84 Ertan FS et al, 2005
HADS
Total score 10/11 92 51 34 96 Leentjens AFG et al, 2001
HADS-D 10/11 100 95 71 100 Mondolo F et al, 2006
HAMD-17 13/14 88 89 74 96 Leentjens AF et al, 2000
IDS-C 11/12 81 79 73 86 Williams JR et al, 2012
IDS-SR 13/14 90 60 61 90 Williams JR et al, 2012
MADRS 14/15 88 89 74 96 Leentjens AF et al, 2000
7/8 72 82 72 82 Silberman CD et al, 2006
NICE screening questions 100 84 54 100 Baillon S et al, 2014
PHQ-9 5/6 66 80 69 77 Williams JR et al, 2012
8/9 100 83 63 100 Chagas MH et al, 2013
PHQ-2 2/3 75 89 70 91 Chagas MH et al, 2011
UPDRS-D 1/2 66 81 81 66 Starkstein SE et al, 2007
WHO-5 12/13 88 74 37 97 Schneider CB et al, 2015
Zung's SDS 54/55 89 83 61 96 Chagas MH et al, 2010
54/55 90 82 59 96 Chagas MH et al, 2013
